The Safe Oil Test
Detect when safety rhetoric is being weaponized to build competitive moats and entrench monopolies.
The Safe Oil Test is a mental model for detecting regulatory capture disguised as safety advocacy. Named after a thought experiment: what if John D. Rockefeller had called his company 'Safe Oil' and lobbied for commonsense kerosene safety standards? The mechanism trains you to ask not just 'is this product dangerous?' but 'who benefits from this specific regulatory proposal?' When the loudest safety advocate is also the incumbent who would gain the most from barriers to entry, that alignment is a red flag. The framework applies to any industry where dominant players call for licensing, pre-approval, or compliance regimes that raise costs for challengers more than for themselves.
- Follow the incentives: the loudest safety advocates are often those who benefit most from the proposed regulation.
- Safety rhetoric and competitive self-interest can be perfectly and sincerely aligned at the same time.
- Regulatory capture is most effective when wrapped in altruistic, public-interest language.
- Approval regimes, licensing costs, and compliance burdens fall hardest on challengers, not incumbents.
- Skepticism about a safety claim should scale with the competitive benefit its advocate receives if that regulation passes.
- Genuine safety solutions usually target the specific risk with the minimum restrictive mechanism necessary.
- Identify the primary safety advocatesName the individuals, companies, or coalitions calling loudest for the regulation. Note their current market position: dominant incumbent, funded challenger, open-source community, or genuinely neutral third party.Pro tipCheck funding sources and board memberships—sometimes neutral-sounding NGOs or think tanks are substantially funded by the incumbents they appear to advise.
- Map the regulation's competitive effectsSketch which players would gain market advantage if the regulation passed and which would face higher compliance costs or outright barriers to entry. A regulation that incumbents can absorb but challengers cannot is a structural moat, regardless of its stated purpose.Pro tipFocus on ongoing compliance costs, not just one-time setup costs. Recurring licensing fees or approval cycles compound against smaller players over time.WarningDo not assume competitive asymmetry is intentional—incumbents sometimes back well-intentioned regulations that happen to advantage them. Intent matters less than effect when assessing market impact.
- Assess proportionality of the safety claimAsk whether the risk cited is real, exaggerated, or hypothetical, and whether the proposed regulatory response is the minimum necessary to address that specific risk. Disproportionate responses—e.g., a full pre-approval regime for a problem that self-policing already handles—signal that non-safety goals may be at work.Pro tipLook for cases where the risk is already being addressed through market mechanisms, liability law, or voluntary coordination. If it is, a new regulatory layer likely serves other purposes.
- Check for moat-building mechanicsDetermine whether the proposed regulation requires expensive licensing, government pre-approval, certified infrastructure, or indefinite review periods. Each of these creates a structural moat that entrenches incumbents who can absorb the cost and slows or blocks new entrants who cannot.Pro tipAsk: 'Would a startup with 20 employees and $10M in the bank be able to comply with this regulation?' If the honest answer is no, the regulation is functionally anti-competitive.
- Apply the Safe Oil InversionExplicitly ask: 'Could the entity calling for this regulation have designed the safety concern to protect its market position, even if they genuinely believe in the concern?' If yes, weight their advocacy accordingly and seek corroborating evidence of the risk from neutral sources before supporting the regulation.Pro tipReframe the advocate's position in the most cynical possible terms, then in the most charitable possible terms. If the cynical framing is equally plausible, you need more evidence before supporting the regulation.WarningAvoid the mirror trap: do not dismiss all safety claims from incumbents as cynical. The Safe Oil Test is a scrutiny multiplier, not a blanket veto on incumbent-backed regulation.
- Calibrate your support or oppositionSupport regulations whose primary advocates have no direct competitive stake in the outcome. Apply heightened scrutiny to regulations whose advocates would directly benefit from the barriers created. Publicly name the competitive dynamic when you oppose, so the debate stays grounded in incentives rather than just safety claims.Pro tipPropose a counter-offer: back the narrowest possible version of the safety measure that addresses the genuine risk without creating approval gates or entry barriers. This separates safety-first advocates from moat-builders—moat-builders will reject it.WarningBe careful not to use the Safe Oil argument to block all regulation by reflex. The goal is competition as the north star, which sometimes requires rules against anti-competitive conduct itself.
Anthropic, one of only two AI companies with substantial revenue, has been associated with safety-focused advocacy including calls for AI oversight regimes. Applying the Safe Oil Test: pre-release model approval requirements would impose compliance burdens far easier for well-capitalized frontier labs to absorb than for smaller startups or open-source projects. The regulation would effectively cement the duopoly's lead under a safety banner, limiting the very competition that would otherwise check their market power.
John D. Rockefeller's actual monopoly succeeded through ruthless price-cutting and rail rebates, not PR. The thought experiment asks: what if he had rebranded as Safe Oil and lobbied for rigorous kerosene safety standards, proper wick-thickness regulations, and licensing of independent refiners? The public debate would have consumed energy on wick standards while Rockefeller built the most powerful monopoly in history, and observers might have called him an effective altruist.
Large pharmaceutical companies have historically supported FDA oversight of dietary supplements—a regulatory layer they can absorb through existing compliance infrastructure but that effectively shuts down smaller supplement brands lacking the capital for clinical testing and approval processes. The safety framing ('protect consumers from unverified supplements') is not wrong, but the competitive effect is unambiguous.
Articulated by David Sacks on the All-In Podcast as a thought experiment comparing Anthropic's AI safety advocacy to how John D. Rockefeller might have used safety rhetoric to protect Standard Oil's monopoly from independent refiners.